Other research analysts have also issued reports about the stock. Alliance Global Partners decreased their price target on shares of Motus GI from $1.75 to $1.40 in a research note on Wednesday, January 26th. Colliers Securities reaffirmed a buy rating on shares of Motus GI in a research note on Tuesday, March 22nd.
Shares of MOTS opened at $0.26 on Monday. The company has a 50-day simple moving average of $0.32 and a two-hundred day simple moving average of $0.42. The company has a debt-to-equity ratio of 1.18, a current ratio of 8.26 and a quick ratio of 8.09. The firm has a market capitalization of $14.39 million, a PE ratio of -0.67 and a beta of 2.40. Motus GI has a one year low of $0.24 and a one year high of $1.22.
Institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC lifted its stake in shares of Motus GI by 654.5% in the fourth quarter. Virtu Financial LLC now owns 346,639 shares of the company’s stock worth $162,000 after buying an additional 300,696 shares in the last quarter. Citadel Advisors LLC lifted its position in Motus GI by 541.2% in the 4th quarter. Citadel Advisors LLC now owns 178,982 shares of the company’s stock valued at $84,000 after acquiring an additional 151,068 shares in the last quarter. Millennium Management LLC boosted its stake in Motus GI by 20.4% during the 3rd quarter. Millennium Management LLC now owns 118,652 shares of the company’s stock valued at $82,000 after purchasing an additional 20,110 shares during the last quarter. Morgan Stanley increased its holdings in shares of Motus GI by 41.7% in the 2nd quarter. Morgan Stanley now owns 51,000 shares of the company’s stock worth $53,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Motus GI in the first quarter worth $26,000. 7.48% of the stock is owned by hedge funds and other institutional investors.
About Motus GI (Get Rating)
Motus GI Holdings, Inc, a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.
- Get a free copy of the StockNews.com research report on Motus GI (MOTS)
- Why Investors Suddenly Love These 2 Software Stocks
- Cloudflare Inc: Struggling but With Great Opportunities
- Volatile Times Are When AbbVie Shines the Brightest
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.